Business Model

Despite intense interest and need, no practical business models have emerged to bring Personalized Medicine to routine clinical practice. The implementation of personalized medicine requires a newly integrated approach. Patient-specific clinical, phenotypic, and genetic profiles will be incorporated to enhance clinical guidelines enabling precisely diagnoses, determine prognosis and find the most suitable treatment approaches, and monitor effectiveness. KEW Group, working with community and academic medical oncologists, molecular geneticists, pathologists, medical informatics specialists, private payers and public policy specialists has developed an approach and is building the required infrastructure to bring Personalized Medicine to cancer care within the setting of established outpatient centers. Our vision is to build a network of cancer care centers with the best medical, administrative, and information technology tools to broadly realize Personalized Medicine for the first time. This will be made possible by leveraging KEW’s proprietary Personalized Medicine platform. Our team has the clinical, operational and technical capabilities to implement these centers in the United States.

KEW Group Strategy

Our strategy is predicated on a multidisciplinary clinical approach that includes patients and their families in critical decision-making. Where there is significant medically-accepted evidence to support the use of genetic/genomic information, our platform will deliver a complete, individual molecular profile at a "lowest total cost" through our own operations and external partners. The platform integrates patient-specific data (e.g. clinical history and genetic profile) with current knowledge of the genetic basis of specific cancers and appropriate and emerging therapeutic approaches. Together these enable the optimal treatment strategies tailored to the patient. Today, this knowledge is unavailable to most community-based physicians in practical or cost-effective ways.

The Platform for Personalized Medicine

We will capture all clinical and genetic data in a structured format and the ability to integrate these data into the EMR/EHR. The genetics/genomics module tracks the rapidly changing genetics knowledge base, identifies appropriate advanced diagnostic tests, sources or conducts the tests, and interprets test results to provide knowledge-based clinical decision support systems to oncologists and the team of cancer care providers. The HIT module facilitates collection, storage, administration, and analysis of highly structured genomic information for use in electronic medical records, the clinical decision support system, and supports pay-for-performance metrics and reimbursement. Our goal is to rapidly, seamlessly and continuously bring new insights back to patients and their clinical teams. These data can be the basis for retrospective and prospective comparative effectiveness analyses and molecular stratification of patients for clinical trials and trial data analysis. Our approach also allows for recruitment of patients that are most likely to benefit from treatment with experimental drugs in clinical trials. In sum, we efficiently and precisely support clinical decision-making while enabling future product and service opportunities.

Our practices and partners will immediately realize financial benefits from scale efficiencies, increased referrals, increased capacity for patients, and other operating efficiencies. Since individual patient diagnoses and treatment plans drive our approach, we can capitalize on opportunities to streamline all processes, eliminating waste throughout, and shortening the total time for each step. Our analyses indicate 20% or greater reductions in total therapeutic costs for many of the most frequent treated solid tumors. Our approach is also exceptionally well suited for a 'pay-for-performance' world where we would be reimbursed based on quality and outcomes. This is the ultimate evolution of the U.S. system and of others internationally.